NASDAQ:CRBP

Corbus Pharmaceuticals Holdings Stock Insider Trading

Healthcare > Biotechnology

Buy CRBP

*Your capital is at risk

$7.38

-0.160 (-2.12%)

At Close: Jun 03, 2026

Corbus Pharmaceuticals Holdings Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 12.51. In total, the insiders bought 2.36M and sold 143.91K CRBP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	12.51
● Buy	2.36M shares
● Sell	143.91K shares
79% Buy Activity Strong Negative Correlation
Buy Signal Medium Confidence May 21, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (79% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 14, 2026 Buy	Common Stock, par value $0.0001 per share A-Award	Cohen Yuval Chief Executive Officer	CEO / President	50 000 Value: $413.0K
Jan 14, 2026 Buy	Stock options (right to buy) A-Award	Moran Sean F. Chief Financial Officer	C-Suite Officer	84 247 Value: $695.9K
Jan 14, 2026 Buy	Common Stock, par value $0.0001 per share A-Award	Moran Sean F. Chief Financial Officer	C-Suite Officer	28 082 Value: $232.0K
Jan 14, 2026 Buy	Stock options (right to buy) A-Award	Smethurst Dominic Chief Medical Officer	Officer	85 095 Value: $702.9K
Jan 14, 2026 Buy	Common Stock, par value $0.0001 per share A-Award	Smethurst Dominic Chief Medical Officer	Officer	28 365 Value: $234.3K
Dec 11, 2025 Sell	Common Stock S-Sale	Cormorant Asset Management, Lp 10 Percent Owner	10% Owner	30 029 Value: $344.0K
Oct 27, 2025 Buy	Stock options (right to buy) M-Exempt	Cohen Yuval Chief Executive Officer	CEO / President	8 973 Value: $38.2K
Oct 27, 2025 Sell	Common Stock, par value $0.0001 per share S-Sale	Cohen Yuval Chief Executive Officer	CEO / President	8 973 Value: $153.8K
Oct 27, 2025 Buy	Common Stock, par value $0.0001 per share M-Exempt	Cohen Yuval Chief Executive Officer	CEO / President	8 973 Value: $38.2K
Oct 24, 2025 Buy	Stock options (right to buy) M-Exempt	Moran Sean F. Chief Financial Officer	C-Suite Officer	12 981 Value: $55.3K
Oct 24, 2025 Sell	Common Stock, par value $0.0001 per share S-Sale	Moran Sean F. Chief Financial Officer	C-Suite Officer	12 981 Value: $220.9K
Oct 24, 2025 Buy	Common Stock, par value $0.0001 per share M-Exempt	Moran Sean F. Chief Financial Officer	C-Suite Officer	12 981 Value: $55.3K
Oct 24, 2025 Buy	Stock options (right to buy) M-Exempt	Cohen Yuval Chief Executive Officer	CEO / President	18 660 Value: $79.5K
Oct 24, 2025 Sell	Common Stock, par value $0.0001 per share S-Sale	Cohen Yuval Chief Executive Officer	CEO / President	18 660 Value: $317.4K
Oct 24, 2025 Buy	Common Stock, par value $0.0001 per share M-Exempt	Cohen Yuval Chief Executive Officer	CEO / President	18 660 Value: $79.5K
Oct 20, 2025 Buy	Stock options (right to buy) M-Exempt	Altmeyer Anne Director	Director	1 060 Value: $5K
Oct 20, 2025 Sell	Common Stock, par value $0.0001 per share S-Sale	Altmeyer Anne Director	Director	1 060 Value: $21.7K
Oct 20, 2025 Buy	Common Stock, par value $0.0001 per share M-Exempt	Altmeyer Anne Director	Director	1 060 Value: $5K
May 30, 2025 Buy	Stock options (right to buy) A-Award	Kung Winston Director	Director	16 000 Value: $118.7K
May 30, 2025 Buy	Common Stock, par value $0.0001 per share A-Award	Kung Winston Director	Director	4 800 Value: $35.6K
May 30, 2025 Buy	Stock options (right to buy) A-Award	Jenkins John Kenneth Director	Director	16 000 Value: $118.7K
May 30, 2025 Buy	Common Stock, par value $0.0001 per share A-Award	Jenkins John Kenneth Director	Director	4 800 Value: $35.6K
May 30, 2025 Sell	Common Stock, par value $0.0001 per share S-Sale	Jenkins John Kenneth Director	Director	2 783 Value: $20.5K
May 30, 2025 Buy	Stock options (right to buy) A-Award	Ben Yong Director	Director	16 000 Value: $118.7K
May 30, 2025 Buy	Common Stock, par value $0.0001 per share A-Award	Ben Yong Director	Director	4 800 Value: $35.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CORBUS PHARMACEUTICALS HOLDINGS

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the act...

Read Full Profile Here